SUBVERIX™

Retatrutide: new phase 3 data presented at EASD 2026 — more on TV•FREE DELIVERY IN POLAND ON ORDERS OVER PLN 200•DISCOVER OUR SUPPLEMENTS — INGREDIENTS AND PRODUCT DETAILS•PEN VIDEO GUIDE — CHOOSE POLISH OR ENGLISH•HAVE A PRODUCT IDEA? SHARE IT WITH SUBVERIX•

SUBVERIX™

Research TV

Research updates, technology and products

SUBVERIX/RESEARCH TV

RESEARCH UPDATE / PHASE 3EASD · 29 SEP 2026

Retatrutide: new phase 3 data presented at EASD 2026

TRIUMPH-2: in adults with obesity or overweight and type 2 diabetes, the 12 mg group achieved an average 20.8% weight reduction at 80 weeks versus 4.0% with placebo (efficacy estimand). The most common adverse events were gastrointestinal. Retatrutide remains investigational; these results do not establish efficacy of SUBVERIX products.

SOURCE: ELI LILLY

Educational content. Some featured products are for research use only. Not medical advice.